Pharma stock soars 20% after 219% QoQ revenue surge. Auro Laboratories reports strong profit rebound and gains WHO-GMP certification.
Pharma stock jumps 20% after stellar quarterly results
Table of Contents
A pharma stock has taken the market by storm, hitting a 20% upper circuit after reporting a 219% quarter-on-quarter (QoQ) jump in revenue and a strong turnaround in profitability. Auro Laboratories Ltd, a micro-cap pharmaceutical company specializing in Active Pharmaceutical Ingredients (APIs) and anti-diabetic drugs such as Metformin Hydrochloride, posted a remarkable financial comeback in its latest quarterly report.
On Thursday, shares of Auro Laboratories Ltd hit the 20% upper circuit, soaring to ₹219.40 from the previous close of ₹182.85. The company’s market capitalization now stands at ₹136.74 crore, reflecting renewed investor optimism following its impressive financial performance.
Q2 Financial Performance: 219% QoQ Revenue Growth
For Q2FY26, Auro Laboratories reported revenue from operations of ₹8.84 crore, marking a 219% QoQ rise from ₹2.77 crore in Q1FY26, and a 185% year-on-year (YoY) increase from ₹3.10 crore in Q2FY25.
The company also delivered a strong profit rebound — turning a ₹0.11 crore loss in Q1FY26 into a ₹0.72 crore net profit in Q2FY26. Year-on-year, profit rose 100%, from ₹0.36 crore in Q2FY25 to ₹0.72 crore in Q2FY26. Earnings per share (EPS) improved sharply to ₹1.15 compared to a negative ₹0.17 in the previous quarter.
Regulatory Milestone: WHO-GMP Certification Secured
Adding to its momentum, Auro Laboratories’ API manufacturing facility at MIDC Tarapur, Maharashtra, has successfully cleared the World Health Organization (WHO) inspection. The plant received a WHO-GMP certification from the Food & Drug Administration, Maharashtra, valid until September 30, 2028 — a major credibility boost for the firm’s export ambitions.
About Auro Laboratories Ltd
Founded in 1992, Auro Laboratories Ltd manufactures Active Pharmaceutical Ingredients (APIs), intermediates, and generic formulations. The company’s expertise lies in anti-diabetic APIs, particularly Metformin Hydrochloride, while also producing compounds for diverse therapeutic categories.
Headquartered in Mumbai, Auro’s manufacturing unit is located at Tarapur, about 120 km from the city. With decades of experience, the firm has built a strong global presence, exporting to Southeast Asia, the Middle East, and Europe — including countries such as Germany, Egypt, Malaysia, Singapore, Spain, South Africa, Brazil, and the United Kingdom.
Investor Takeaway
This pharma stock’s strong operational turnaround, robust revenue growth, and WHO certification signal improved fundamentals and global credibility. While the rally reflects investor confidence, traders should still conduct due diligence before taking positions in micro-cap stocks.
Disclaimer:
This article is for informational purposes only and not investment advice. Market investments carry inherent risks. Please consult your financial advisor before making any investment decisions.
Also Read: Diamond Power Infrastructure Limited Shares Jump
